Concepedia

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

Thomas Vogt, Christian Hafner, K. Bross, Frauke Bataille, Karl‐Walter Jauch, Anna Berand, Michael Landthaler, Reinhard Andreesen, Albrecht Reichle

Cancer · 2003 · 143 citations · 23 references

DOI

Abstract

This new triple combination of low-dose metronomic trofosfamide, pioglitazone, and rofecoxib may represent a feasible new alternative in the palliative treatment of patients with advanced malignant vascular tumors.

References

23

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Timothy M. Browder, Catherine Butterfield, Birgit M. Kräling et al. · PubMed · 2000 · 1.6K citations

, , +14

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Giannoula Klement, Sylvain Baruchel, Janusz Rak et al. · Journal of Clinical Investigation · 2000 · 1.2K citations · Full text

PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs

Tong‐Chuan He, Timothy A. Chan, B Vogelstein et al. · Cell · 1999 · 1.1K citations · Full text

Differentiation and reversal of malignant changes in colon cancer through PPARγ

Pasha Sarraf, Elisabetta Mueller, Daniel M. Jones et al. · Nature Medicine · 1998 · 969 citations

, , +9

Terminal Differentiation of Human Breast Cancer through PPARγ

Elisabetta Mueller, Pasha Sarraf, Peter Tontonoz et al. · Molecular Cell · 1998 · 841 citations · Full text

, , +5